Late Toxicity in Breast Cancer Patients Treated With Breast-conserving Surgical Procedures and Radiotherapy Using the Simultaneous Integrated Boost Technique

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5043 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-31

Study Completion Date

2017-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In summary, breast conserving therapy (BCT) is an effective, save and widely used treatment technique for early breast cancer. Radiotherapy has shown to give better local control and survival benefit and is an integrated part of BCT. The simultaneous integrated boost (SIB) technique is a new treatment technique in breast irradiation. In this technique the whole breast is irradiated simultaneous with boosting the tumour bed, as part of BCT. Late radiation-induced toxicity has not been investigated in patients treated with radiotherapy using this technique. Proposed study will study the late radiation-induced toxicity, describe patients-rated complaints, quality of life, survival and local control curves in patients treated for early breast cancer with breast-conserving surgery in combination with radiotherapy with the SIB technique as compared to sequential radiotherapy treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Boost Versus no Boost Irradiation of Early Breast Cancer

NCT02295033

Breast Cancer

COMPLETED PHASE3

Simultaneous Integrated Boost Technique in Breast Cancer Radiotherapy

NCT04535895

Breast Cancer Radiotherapy Side Effect

WITHDRAWN NA

Highly Accelerated Dose-Integrated Radiotherapy in 5 Fractions in Breast Cancer

NCT04098926

Breast Cancer Radiotherapy

COMPLETED NA

Hypofractionated Radiation Therapy With Concomitant Boost in Treating Women After Breast Conserving Surgery

NCT03320421

Breast Cancer Female

COMPLETED NA

Comparison of Acute Toxicity and Cost Between Whole Breast Irradiation With Sequential Boost and Simultaneous Integrated Boost After Breast Conserving Surgery.

NCT01973634

Radiotherapy After Breast Conserving Surgery

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Simultaneous Integrated Boost Technique

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* WHO performance status 0-2.
* Invasive breast cancer or ductal carcinoma in situ (DCIS).
* Stage I-III breast cancer or DCIS.
* Treated with curative radiotherapy of the breast (as part of breast conserving therapy) with simultaneous integrated boost technique, with or without irradiation of the regional (including internal mammary) lymph nodes.

Exclusion Criteria

* Previous thoracic radiotherapy.
* Previous history of malignancy, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin.
* Bilateral (synchrone) invasive breast cancer.
* Treatment prior to surgery (i.e. neoadjuvant chemotherapy, neoadjuvant hormonal therapy, pre-operative radiotherapy).
* Distant metastases at diagnosis (M1).
* Unsufficient knowledge of Dutch language.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No